Discovery could pave the way for developing therapies to treat nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Discovery could pave the way for developing therapies to treat nonalcoholic steatohepatitis Download PDF Copy Reviewed UT Southwestern Medical Center Dec 27 2022 UT Southwestern immunologists have uncovered a key pathogenic event prompted by obesity that can trigger severe forms of nonalcoholic fatty liver disease and potential liver failure. The finding, published in Immunity , could pave the way for developing therapies to treat nonalcoholic steatohepatitis (NASH). The team led by Zhenyu Zhong, Ph.D., and Shuang Liang, Ph.D., Assistant Professors of Immunology, revealed that persistent obesity can damage a macrophage receptor, called TREM2, thereby disabling a critical function that otherwise keeps liver inflammation in check. The imbalance then fuels chronic liver inflammation to enable NASH development. NASH is an aggressive form of nonalcoholic fatty liver disease (NAFLD) – a spectrum of chronic liver disorders that start out as benign fatty liver but can progress into more advanced disease stages including NASH, cirrhosis and even hepatocellular carcinoma (HCC), the dominant form of primary liver cancer. The underlying molecular mechanisms that cause fatty liver disease to progress to NASH and beyond have eluded researchers, creating significant hurdles to developing effective therapies. Bridging this knowledge gap, Drs. Zhong and Liang discovered that dietary obesity upregulates TREM2 expression in the liver-infiltrating macrophages – a critical population of immune cells responsible for removing lipid-damaged hepatocytes. "The clearance of these damaged cells by macrophages (a process also referred to as efferocytosis) is key to maintaining liver immune silence in the fatty liver to prevent chronic inflammation and NASH," Dr. Liang said. Upon examination of TREM2 expression during NASH development, the researchers unexpectedly found that persistent obesity significantly impaired macrophage-dependent removal of lipid-damaged hepatocytes by inducing TREM2 cleavage and inactivation. We discovered that two proinflammatory cytokines, TNF and IL-1β, activate a proteinase named ADAM17 in macrophages that in turn cleaves and inactivates TREM2. This leads to aberrant accumulation of lipid-loaded, dying hepatocytes in the liver where they cause chronic liver inflammation and subsequent NASH development. We reason that blocking TREM2 cleavage to restore the macrophage's ability to remove lipid-damaged hepatocytes has the great potential to treat NASH." Dr. Zhenyu Zhong, Ph.D., Member of the Harold C. Simmons Comprehensive Cancer Center and Cancer Prevention and Research Institute of Texas Scholar in Cancer Research at UT Southwestern Additionally, they discovered that the cleaved product, the soluble TREM2 (sTREM2), whose abundance is drastically elevated in the circulation of NASH-bearing mice and patients, can serve as a noninvasive biomarker for NASH. The Zhong Lab is focused on understanding the fundamental molecular mechanisms by which chronic liver inflammation is established. "With the unprecedented obesity epidemic, NASH has become a major chronic liver disorder, affecting approximately 3%-5% of the global population," said Dr. Zhong, a member of the Division of Basic Science of UT Southwestern's Graduate School of Biomedical Sciences. "By deploying a combination of biochemical, genetic, molecular, immunological, imaging, and histochemical tools as well as single-cell 'omics' analyses, our ultimate goal is to reveal the fundamental molecular mechanisms underlying chronic liver inflammation and explore if such novel mechanistic insights could be applied to benefit liver repair and regeneration after injury, thereby preventing NAFLD progression into NASH and HCC." Related Stories Liver-derived protein supports bone health in males Cornell study finds existing drug could boost liver cancer immunotherapy Obesity drives one in ten infectious disease deaths Other UTSW researchers who contributed to the study are Xiaochen Wang, Chuanli Zhou, Danhui Liu, Naoto Fujiwara, Naoto Kubota, Arielle Click, Polly Henderson, Janiece Vancil, Cesia Ammi Marquez, and Yujin Hoshida. This study was supported by grants from the American Association for the Study of Liver Diseases, the Cancer Prevention and Research Institute of Texas, and the National Institutes of Health. Additional support included computational support from the BioHPC supercomputing facility in the Lyda Hill Department of Bioinformatics at UT Southwestern, the UTSW Flow Cytometry Core facility, and UTSW Circle of Friends Award in Cancer Research, among others. Source: UT Southwestern Medical Center Journal reference: Wang, X., et al. (2022) Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity. doi.org/10.1016/j.immuni.2022.11.013 . Posted in: Medical Science News | Medical Research News | Medical Condition News Comments (0) Download PDF Copy Suggested Reading Researchers develop new score to predict the risk of liver cancer Obesity drives shared genetic risk behind many chronic disease combinations Research shows the effect of losing weight in preventing multiple diseases Study explores whether a bidirectional causal link exists between MASLD and sarcopenia SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies Do cocoa flavanols influence heart and fatty liver risk factors? Obesity sharply increases hospitalisation risk from infections, global analysis shows Low-grade inflammation connects aging, obesity and cognitive impairment Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s impenetrable fortress Weekend holiday rehabilitation supports recovery in elderly hip fracture patients Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Newsletters you may be interested in Genetics ( Subscribe or Preview ) Digital Pathology & Histology ( Subscribe or Preview ) Hepatology ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Breastfeeding and healthy infant diets may help lower obesity risk by age nine